Cantor Fitzgerald Downgrades Cognition Therapeutics (CGTX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CGTX Hot Sheet
Price: $0.68 --0%
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 2
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 2
Join SI Premium – FREE
Cantor Fitzgerald analyst Charles Duncan downgraded Cognition Therapeutics (NASDAQ: CGTX) from Overweight to Neutral.
For an analyst ratings summary and ratings history on Cognition Therapeutics click here. For more ratings news on Cognition Therapeutics click here.
Shares of Cognition Therapeutics closed at $2.37 yesterday.
You May Also Be Interested In
- Goldman Sachs Downgrades Regis Resources Ltd. (RRL:AU) (RGRNF) to Sell
- Goldman Sachs Downgrades Genesis Minerals Ltd (GMD:AU) to Neutral
- Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
